# Cannabis Medicine in Family Practice: Evidence-Based Dosing Strategies from Endocannabinoid System Research > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/evidence-based-cannabis-dosing-family-practice/ > **Published:** 2026-05-28T23:52:56-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:53:48-04:00 > **Clinical Summary:** Explore evidence-based cannabis dosing strategies in family practice informed by endocannabinoid system research for improved clinical outcomes. --- Table of Contents - [Clinical Takeaway](#Clinical_Takeaway) - [#1 Test-Retest Reliability of Standardized Diagnostic Interviews for Common Adult Psychiatric Disorders: A Systematic Review and Meta-Analysis.](#1_Test-Retest_Reliability_of_Standardized_Diagnostic_Interviews_for_Common_Adult_Psychiatric_Disorders_A_Systematic_Review_and_Meta-Analysis) - [What This Study Teaches Us](#What_This_Study_Teaches_Us) - [Why This Matters Clinically](#Why_This_Matters_Clinically) - [Study Snapshot](#Study_Snapshot) - [Where This Paper Deserves Skepticism](#Where_This_Paper_Deserves_Skepticism) - [Dr. Caplan’s Take](#Dr_Caplans_Take) - [Clinical Bottom Line](#Clinical_Bottom_Line) - [Related](#Related) #### Clinical Takeaway Standardized diagnostic interviews show variable but generally acceptable test-retest reliability across common adult psychiatric disorders, meaning repeated administrations of the same structured interview do not always produce identical diagnoses. Clinicians should be aware that no single diagnostic tool is perfectly consistent, and results may shift depending on the disorder being assessed, the time between interviews, and the specific instrument used. This reinforces the importance of using diagnostic interviews as one component of a comprehensive clinical evaluation rather than relying on them as a definitive standalone measure. ### #1 Test-Retest Reliability of Standardized Diagnostic Interviews for Common Adult Psychiatric Disorders: A Systematic Review and Meta-Analysis. **Citation:** Xie Weiyi et al. *Test-Retest Reliability of Standardized Diagnostic Interviews for Common Adult Psychiatric Disorders: A [Systematic Review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) and Meta-Analysis.* JAMA network open. 2026. PMID: 42207515. **Study type:** Journal Article, [Systematic Review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/), Meta-Analysis  |  **Topic area:** Depression  |  **CED Score:** 19 Design: 6 Journal: 4 N: 4 Recency: 3 Pop: 1 Human: 1 Risk: 0 **Abstract:** IMPORTANCE: Standardized diagnostic interviews (SDIs) are structured assessments based on established criteria to improve the consistency and reliability of diagnoses. The pooled test-retest reliability of SDIs for adult psychiatric disorders is unknown. OBJECTIVES: To estimate the test-retest reliability of SDIs used to classify common adult psychiatric disorders, examine variations in test-retest reliability between disorders, and assess prespecified factors associated with between-study heterogeneity. DATA SOURCES: MEDLINE, Embase, Emcare, PsycINFO, and Applied Social Sciences Index and Abstracts were searched without date or language limitations from inception until September 2025. References of eligible articles and relevant reviews were also screened. STUDY SELECTION: Primary studies that evaluated test-retest reliability of SDIs assessing adult psychiatric disorders were selected. Disorders were selected based on estimated prevalence in the general adult population, clinical relevance, and frequent appearance in SDIs. DATA EXTRACTION AND SYNTHESIS: Data were extracted and study quality was assessed based on the Consensus-based Standards for the Selection of Health Measurement Instruments checklist. Multilevel random-effects meta-analysis and meta-regression were performed. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. MAIN OUTCOMES AND MEASURES: Test-retest reliability estimates (Cohen κ) of SDI-based adult psychiatric disorder diagnoses. Pooled estimates were calculated for 5 groups of mental disorders (anxiety, bipolar, depressive, personality, and nonaffective psychoses) and 8 groups of substance use disorders (SUDs; alcohol, cannabis, cocaine, hallucinogens, opioids, sedatives, stimulants, and tobacco). RESULTS: Fifty-seven studies were analyzed, 46 of which were included in the meta-analysis (535 κ estimates; N = 8146 participants [mean age range, 22.0-54.3 years]). The pooled estimate of SDI test-r ### What This Study Teaches Us This meta-analysis pooled test-retest reliability data across standardized diagnostic interviews for common psychiatric disorders and substance use disorders. It provides the first systematic estimate of how consistently these structured interviews classify the same person on repeated assessment. ### Why This Matters Clinically Clinicians rely on diagnostic interviews to establish psychiatric diagnoses that guide treatment selection and prognosis. Knowing the actual reliability of these tools (not just assuming they work) helps you interpret whether a diagnosis is stable or potentially an artifact of measurement error, especially when making major treatment decisions. ### Study Snapshot **Study Design** [Systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) and meta-analysis of test-retest reliability studies using multilevel random-effects models **Population** Adult subjects assessed with standardized diagnostic interviews for psychiatric and substance use disorders; N of included studies and total participants not specified in abstract **Intervention** Not applicable. This is an observational synthesis of reliability coefficients (Cohen kappa) from existing studies **Primary Outcome** Test-retest reliability (Cohen kappa) of standardized diagnostic interviews for five psychiatric disorder groups and eight substance use disorder groups **Key Result** Not specified in abstract. The abstract states objectives and methods but does not report the actual pooled kappa values or reliability findings ### Where This Paper Deserves Skepticism The abstract provides no actual numerical results, making it impossible to evaluate the magnitude of reliability or identify which disorders showed poor agreement. The search period ends September 2025, which means this is a future-dated publication being reviewed prematurely or the abstract itself is incomplete. Without knowing how many studies were included, the diversity of interview types tested, or time intervals between test and retest administrations, we cannot assess whether heterogeneity was adequately explained. ### Dr. Caplan’s Take I appreciate that someone is finally systematizing what we know about the test-retest performance of our diagnostic tools. In [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) and all of psychiatry, we often cite structured interviews as the gold standard without actually knowing how reliably they perform across repeated administrations. That said, I’d want to see the actual data before drawing conclusions. The absence of results in this abstract is frustrating, and I’d need the full paper to comment on what this means for my diagnostic confidence in clinical practice. ### Clinical Bottom Line This systematic review is methodologically sound in approach but cannot be meaningfully evaluated without the actual reliability estimates and disorder-specific findings reported in the full paper. **Clinical Angles to Consider:** - Does this suggest a role in treatment-resistant depression or as monotherapy? - How does mood-related ECS dysregulation contextualize this finding? - What monitoring frequency is appropriate given this data?  |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/42207515/)[DOI ↗](https://doi.org/10.1001/jamanetworkopen.2026.15039) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20Medicine%20in%20Family%20Practice%3A%20Evidence-Based%20Dosing%20Strategies%20from%20Endocannabinoid%20System%20R...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56704)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56704)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20Medicine%20in%20Family%20Practice%3A%20Evidence-Based%20Dosing%20Strategies%20from%20Endocannabinoid%20System%20R...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56704)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) RELATED READING AT CED CLINIC Continue exploring the evidence [Medical Cannabis Evidence-Based Care: Endocannabinoid System Clinical Research and Cannabinoid Dosing in Family Medicine](https://cedclinic.com/prenatal-cannabis-polysubstance-use-risks/) Explore [clinical research](https://cedclinic.com/endocannabinoid-system-stroke-prevention/) on [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) and cannabinoid dosing tailored for family medicine practitioners. [Read More](https://cedclinic.com/prenatal-cannabis-polysubstance-use-risks/) [Endocannabinoid System Research: Cannabis Mental Health Care](https://cedclinic.com/clinical-trial-cannabis-mental-health-research/) Learn about the role of [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) research in advancing cannabis-based mental health treatments. [Discover Insights](https://cedclinic.com/clinical-trial-cannabis-mental-health-research/) [Endocannabinoid System & GLP-1 Receptor Mental Health Evidence](https://cedclinic.com/glp-1-receptor-agonists-mental-health-impact/) Review evidence linking the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) and GLP-1 receptors in mental health for informed [cannabis therapy](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). [Learn More](https://cedclinic.com/glp-1-receptor-agonists-mental-health-impact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).